CompletedPhase 1NCT02502708

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Studying Gliosarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
NewLink Genetics Corporation
Principal Investigator
Gene Kennedy, MD, MD
NewLink Genetics Corporation
Intervention
Indoximod(drug)
Enrollment
81 enrolled
Eligibility
3-21 years · All sexes
Timeline
2015 – 2020

Study locations (5)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02502708 on ClinicalTrials.gov

Other trials for Gliosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Gliosarcoma →

← Back to all trials